---
title: DiGA Pricing and Reimbursement: How the German System Works
description: DiGA reimbursement is not a one-way revenue escalator. How prices are set, why they decline, and what startups should model before committing to the German path.
authors: Tibor Zechmeister, Felix Lenhard
category: Funding, Business Models & Reimbursement
primary_keyword: DiGA pricing reimbursement Germany
canonical_url: https://zechmeister-solutions.com/en/blog/diga-pricing-reimbursement
source: zechmeister-solutions.com
license: All rights reserved. Content may be cited with attribution and a link to the canonical URL.
---

# DiGA Pricing and Reimbursement: How the German System Works

*By Tibor Zechmeister (EU MDR Expert, Notified Body Lead Auditor) and Felix Lenhard.*

> **DiGA is often sold to founders as a straight line from CE mark to German reimbursement. The reality is messier. Manufacturers Tibor has spoken to describe initial reimbursement as acceptable, with rates that tend to decline over time. Germany has more than 90 statutory health insurance funds, and there is no single umbrella acceptance. Before a startup commits, it should model the full curve, not the first data point.**

**By Tibor Zechmeister and Felix Lenhard.**

## TL;DR
- DiGA (Digitale Gesundheitsanwendung) is Germany's reimbursement pathway for digital health applications that already hold a CE mark under MDR.
- CE marking is a prerequisite, not a qualification. DiGA requires clinical and economic evidence that goes beyond minimal MDR Class I conformity.
- Initial reimbursement per user can look attractive. Several DiGA-listed manufacturers report that rates tend to decline as the product remains in the system .
- Germany has more than 90 statutory health insurance funds (gesetzliche Krankenkassen). There is no single payer decision and no umbrella acceptance across all funds .
- DiGA price negotiation involves the GKV-Spitzenverband (GKV-SV) and follows a defined procedure that includes a provisional reimbursement window and a negotiated price phase .
- The ROI case is not a one-way escalator. A startup that models DiGA as a flat annuity will misprice its runway.

## Why this matters

Founders hear a simple story about DiGA. Build a digital health product. Get a CE mark. Apply to BfArM. Land on the DiGA list. Collect reimbursement from German statutory health insurance. Scale from there.

The story is attractive because it looks like the first real European reimbursement pathway purpose-built for software. It was created under the Digitale-Versorgung-Gesetz (DVG) in 2019, and for a while it was the most concrete answer to the question every digital health founder asks: "Will somebody actually pay for this?" .

Tibor has not taken a product through DiGA directly. What he has done is talk to founders who did. The pattern from those conversations is consistent enough to matter. The first rate a product gets after listing is usually acceptable. The rate that applies two years later is often lower. Some technologies become uneconomic to continue. That is not a failure of any one manufacturer. It is a feature of how the German system sets and revisits prices, and a consequence of a payer landscape that is far more fragmented than it looks from the outside.

Felix has coached startups that assumed DiGA revenue would arrive as a smooth annuity indexed to user growth. In every case, the actual reimbursement curve deviated from the founder's model within the first twelve months. This post is the honest version of how DiGA pricing works for startups.

## What the German system actually is

The DiGA pathway is created by SGB V (the German Social Code, Book V) and operationalised by BfArM (Federal Institute for Drugs and Medical Devices) through the DiGA-Verzeichnis, the official directory of approved applications .

Three roles matter:

1. **BfArM.** Runs the DiGA listing process, reviews the application, and decides whether a product enters the directory on a provisional or permanent basis. Assessment criteria include safety, functional suitability, quality, interoperability, data protection, data security, and positive healthcare effects (positive Versorgungseffekte) .
2. **GKV-Spitzenverband (GKV-SV).** The umbrella association of statutory health insurance funds. GKV-SV is the counterparty that negotiates the reimbursement price with the manufacturer after the listing window begins .
3. **The individual statutory health insurance funds.** More than 90 funds actually reimburse the application when a patient presents a prescription or direct request . Each fund manages its own contract processing, patient communication, and activation workflow.

CE marking is necessary but not sufficient. A DiGA must be a medical device under MDR, typically a Class I or Class IIa software-as-a-medical-device product under Annex VIII Rule 11. The classification result drives the MDR conformity assessment route. It does not drive the DiGA decision.

BfArM wants to see more than conformity. It wants to see evidence that the product delivers a positive healthcare effect (either a medical benefit or a structural-procedural improvement such as better adherence or patient access). This is where startups with minimal MDR evidence collide with the actual bar.

## A worked example

Consider a seed-stage startup with a Class I self-certified mental health application. CE marking was achieved with the minimum viable technical documentation: intended purpose, GSPR matrix, risk file under EN ISO 14971:2019+A11:2021, software lifecycle documentation under EN 62304:2006+A1:2015, usability file, PMS plan, and a declaration of conformity. Total MDR evidence budget: roughly what a founder would consider reasonable for a Class I device pre-seed.

The founder now wants to apply for DiGA. The model on the investor deck assumes a per-user reimbursement of a certain amount per 90-day prescription, a linear ramp in user activations across all major statutory funds, and a stable rate for the first three years. That model looks defensible in isolation.

The reality a DiGA applicant faces is different:

- **Evidence gap.** The MDR Class I file does not include the quantitative and qualitative evidence of a positive healthcare effect at the level BfArM expects. Either the product enters the provisional listing window with a commitment to generate that evidence during the window, or the application is declined .
- **Provisional price.** During the provisional listing window, the manufacturer can set an initial price that applies while the evidence is being generated .
- **Negotiated price.** After the window closes and the evidence is reviewed, the price is renegotiated with GKV-SV. In several manufacturer-reported cases, the negotiated price is lower than the provisional price. In some cases, materially lower .
- **Fund-level friction.** Even with a listing and a price, each of the 90-plus statutory funds handles patient activation differently. A startup that assumes instant and uniform access across all funds is overestimating near-term revenue .

The same startup, with the same CE mark, will see a cash flow curve that bends downward when the provisional window closes. Not because the product is bad, but because the system is designed to revisit price once real-world evidence is in hand. That is not a bug. It is the German model at work.

## The Subtract to Ship playbook

Felix's Subtract to Ship methodology argues for removing assumptions before adding spend. The DiGA pathway is a clean test case. Here is how a resource-constrained startup should approach it.

**Step 1: Decide if DiGA is the right beachhead at all.** Germany is the biggest single European market. That is true. It is not the same as saying Germany is the easiest market. A product whose clinical evidence story is strong in another jurisdiction may be better served launching there first and entering Germany later. This is a business-model decision before it is a regulatory decision.

**Step 2: Talk to at least three DiGA-listed manufacturers before spending any money on an application.** Tibor says this explicitly. The DiGA system is documented, but the operational reality is learned only from founders who have been through it. Ask about the provisional-to-negotiated price delta. Ask about fund-level activation friction. Ask what they would do differently.

**Step 3: Model a realistic reimbursement curve, not a flat annuity.** Assume the provisional price holds for the provisional window. Assume a negotiated price that is materially lower than the provisional price. Assume a fund-activation ramp measured in months, not weeks. If the business case still works under these assumptions, the DiGA path is defensible. If it only works under the optimistic version, stop.

**Step 4: Budget clinical evidence generation as a separate line item.** The positive healthcare effect evidence is not an MDR deliverable. It is a DiGA deliverable. Treat it as a standalone study with a standalone budget. Founders who fold it into the MDR clinical evaluation plan underspend and underdeliver.

**Step 5: Avoid the Class I self-certification trap.** Tibor has seen founders assume that a Class I self-certified declaration of conformity will satisfy BfArM because it satisfies MDR. It does not. The MDR classification is the regulatory floor. The DiGA evidence bar is higher. Underestimating this is one of the more expensive mistakes a first-time DiGA applicant can make.

**Step 6: Engage GKV-SV early, indirectly.** GKV-SV is not a counterparty a seed-stage founder talks to directly on day one. But understanding the price-negotiation framework before submitting is a basic due diligence step. The documentation is public. Reading it is free .

**Step 7: Plan for renegotiation from day one.** The price on the listing day is not the price forever. Build the pricing model on the expected negotiated price and treat the provisional window as a bridge, not a permanent state.

The thread through all seven steps is the same. DiGA is a real pathway. It is not a substitute for a real business case. Startups that treat it as a free ride to German reimbursement are the ones whose founder interviews start with "we thought it would be different."

## Reality Check

A short diagnostic for founders considering DiGA as a revenue pathway.

1. Have you spoken to at least three DiGA-listed manufacturers about their real reimbursement curve? If not, stop and do that first.
2. Does your financial model assume a flat reimbursement rate for three years, or does it model a negotiated price decline after the provisional window?
3. Do you have a budget line for clinical evidence generation specifically for the DiGA positive healthcare effect requirement, separate from your MDR clinical evaluation?
4. Have you confirmed the MDR classification of your product under Annex VIII Rule 11 and understood whether your evidence is sufficient for the BfArM bar, not just the MDR bar?
5. Does your go-to-market plan account for the fact that patient activation varies across more than 90 statutory health insurance funds?
6. Have you read the current BfArM DiGA guide and the DiGA-Verordnung in their latest versions, or are you working from a blog post written in 2021?
7. If DiGA reimbursement declined by a material amount at the negotiated-price stage, would your company still have runway?
8. Is DiGA your beachhead because it is the best fit, or because it is the best story for your next investor meeting?

If three or more of these questions make you uncomfortable, the honest next step is not a BfArM application. It is another round of founder conversations.

## Frequently Asked Questions

**Is DiGA the same as CE marking?**
No. CE marking under MDR is a prerequisite for DiGA listing. DiGA is a separate reimbursement pathway with its own evidence bar, administered by BfArM under German national law.

**Can a Class I self-certified software product get into DiGA?**
Technically possible if the product genuinely qualifies as Class I under MDR Annex VIII Rule 11, but founders consistently underestimate how much additional clinical and economic evidence BfArM requires beyond the Class I conformity file .

**How many statutory health insurance funds are there in Germany?**
More than 90 at the time of writing. The number changes as funds merge. There is no single umbrella acceptance, so listing on the DiGA directory does not guarantee uniform reimbursement behaviour across all funds .

**Why does the reimbursement rate decline over time?**
Because the German system renegotiates the price after the provisional listing window closes and real-world evidence is available. Several DiGA-listed manufacturers have reported to Tibor that the negotiated price is lower than the provisional price .

**Should a seed-stage startup commit to DiGA as its primary revenue plan?**
Only after modelling a realistic reimbursement curve, budgeting for DiGA-grade clinical evidence, and speaking to DiGA-listed founders. Treating DiGA as guaranteed German market access is the single most common error Tibor and Felix see in this space.

**Who actually sets the DiGA price?**
Provisionally, the manufacturer sets it. After the provisional window, the price is negotiated with GKV-SV under rules defined in the DiGA-Verordnung, with arbitration fallback if agreement cannot be reached .

## Related reading
- [Reimbursement for digital health in Europe beyond DiGA](/blog/reimbursement-digital-health-europe-beyond-diga) because DiGA is one of several national digital health reimbursement pathways, not the only one.
- [German reimbursement for medical devices](/blog/german-reimbursement-medical-devices) for the broader German payer landscape that DiGA sits inside.
- [Reimbursement strategy Europe startup guide](/blog/reimbursement-strategy-europe-startup-guide) to place DiGA inside a realistic European go-to-market sequence.
- [MDR classification Rule 11 software](/blog/mdr-classification-rule-11-software) because the MDR classification result shapes the conformity route before DiGA is even an option.
- [MedTech business model analysis](/blog/medtech-business-model-analysis) to pressure-test whether DiGA is a revenue plan or a funding narrative.

## Sources
1. Regulation (EU) 2017/745 on medical devices, consolidated text. Article 2, Article 51, Annex VIII Rule 11.
2. SGB V (German Social Code, Book V), provisions on digital health applications .
3. BfArM, The Fast-Track Process for Digital Health Applications (DiGA) according to § 139e SGB V – A Guide for Manufacturers, Service Providers and Users. Current version .
4. Digitale Gesundheitsanwendungen-Verordnung (DiGAV), consolidated version .
5. GKV-Spitzenverband, framework documents on DiGA price negotiation .
6. Tibor Zechmeister interview notes from DiGA-listed manufacturers (anecdotal, not statistical).

---

*This post is part of the [Funding, Business Models & Reimbursement](https://zechmeister-solutions.com/en/blog/category/funding-reimbursement) cluster in the [Subtract to Ship: MDR Blog](https://zechmeister-solutions.com/en/blog). For EU MDR certification consulting, see [zechmeister-solutions.com](https://zechmeister-solutions.com).*